Preimplantation Genetic Diagnosis Market, By Type, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Preimplantation genetic diagnosis (PGD) is the genetic profiling of the pre implantable embryos and oocytes before their implantation. The preimplantation genetic diagnosis is similar to that of the parental diagnosis in case of screening for a particular genetic disease. The PGD is advantageous in a way that helps to avoid selective pregnancy termination by the development and growth of the healthy fetus. PGD serves as an addendum to assisted reproductive technology. The preimplantation genetic diagnosis is required in vitro fertilization, in order to obtain oocytes from the embryos for the genetic evaluation of the diseased or disease-free conditions. In simpler terms, the preimplantation genetic diagnosis is a technique that is used to identify embryos at risk.

Restraints of the Global Preimplantation Genetic Diagnosis Market

Major factors hampering the growth of the preimplantation genetic diagnosis market during the forecast period constitutes of non-availability of embryos for transfer.

Key features of the study:

• This report provides in-depth analysis of the global preimplantation genetic diagnosis market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year

• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

• It profiles leading players in the global preimplantation genetic diagnosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans

• Key companies covered as a part of this study include Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.

• Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics

• The global preimplantation genetic diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

• Global Preimplantation Genetic Diagnosis Market, By Type:
  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others (for disability, adult onset disease)
• Global Preimplantation Genetic Diagnosis Market, By End User:
  • Diagnostic Laboratories
  • Hospitals
  • Clinics
• Global Preimplantation Genetic Diagnosis Market, By Geography:
  • North America
• By Type
  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others (for disability, adult onset disease)
• By End User
  • Diagnostic Laboratories
  • Hospitals
  • Clinics
• By Country:
  • U.S.
  • Canada
  • Europe
• By Type
  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others (for disability, adult onset disease)
• By End User
  • Diagnostic Laboratories
  • Hospitals
  • Clinics
• By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
• By Type
  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others (for disability, adult onset disease)
• By End User
  • Diagnostic Laboratories
  • Hospitals
  • Clinics
• By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
• By Type
  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others (for disability, adult onset disease)
• By End User
  • Diagnostic Laboratories
  • Hospitals
  • Clinics
• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East:
• By Type
  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others (for disability, adult onset disease)
• By End User
  • Diagnostic Laboratories
  • Hospitals
  • Clinics
• By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
• By Type
  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single gene disorders
  • HLA Typing
  • Gender Selection
  • Others (for disability, adult onset disease)
• By End User
  • Diagnostic Laboratories
  • Hospitals
  • Clinics
• By Country/Region:
  • Central Africa
  • South Africa
  • North Africa
• Company Profiles
  • Amgen Inc.*
• Company Overview
• Product Portfolio
• Financial Performance
• Key Strategies
• Recent Developments
  • Quest Diagnostics
  • Vertex
  • PerkinElmer, Inc.
  • F. Hoffman-La-Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • Laboratory Corporation of America Holdings
  • Abbott Laboratories
  • Illumina, Inc.
  • Natera Inc.
  • CooperGenomics Inc.
  • Reproductive Genetics Institute, Inc.
  • Genea Ltd.
  • Invitae Corporation
  • CombiMatrix Corporation

"*" marked represents similar segmentation in other categories in the respective section.